Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Historical highlights and unsolved problems in glycogen storage disease type 1.

Shimon W Moses1

  • 1Department of Paediatrics, Soroka Medical Centre, POB 151, Beersheva 84101, Israel. moses@bgumail.bgu.ac.il

European Journal of Pediatrics
|October 10, 2002
PubMed
Summary

Glycogen storage disease type 1 (GSD1) involves glucose-6-phosphatase (G6Pase) deficiency, with subtypes linked to G6Pase or G6PT gene mutations. Management focuses on blood glucose control, but long-term complications persist, highlighting research gaps.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of descent and stay at a Dead Sea resort (low altitude) on patients with systolic congestive heart failure and an implantable cardioverter defibrillator.

The Israel Medical Association journal : IMAJ·2011
Same author

The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea.

International journal of dermatology·2007
Same author

The Dead Sea, a unique natural health resort.

The Israel Medical Association journal : IMAJ·2006
Same author

Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases.

European journal of human genetics : EJHG·2003
Same author

The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies.

Current molecular medicine·2002

Area of Science:

  • Biochemistry and Genetics of Metabolic Disorders
  • Molecular basis of Glycogen Storage Disease Type 1 (GSD1)
  • Enzyme deficiencies and their clinical manifestations

Background:

  • Glycogen Storage Disease Type 1 (GSD1) is characterized by glucose-6-phosphatase (G6Pase) deficiency.
  • Subtypes of GSD1 include defects in G6Pase (GSD1a) and the glucose-6-phosphate transporter (G6PT, GSD1b).
  • GSD1c and GSD1d are now understood to be related to G6PT gene mutations.

Observation:

  • G6PT deficient patients exhibit leukocyte abnormalities, including numerical and functional defects.
  • Inflammatory bowel disease is frequently observed in GSD non-1a patients, potentially linked to leukocyte issues.
  • Gene therapy approaches using adenoviral vectors have shown success in correcting GSD1 abnormalities in animal models.

Findings:

Related Experiment Videos

  • GSD1 patients are classified into GSD1a (G6Pase deficiency) and non-1a (primarily G6PT deficiency).
  • Dietary management, including nocturnal glucose infusions or uncooked cornstarch, significantly improves quality of life and prognosis.
  • Endogenous glucose production increases with age in GSD1 patients, correlating with improved fasting tolerance.

Implications:

  • Understanding GSD1 subtypes is crucial for targeted diagnosis and management.
  • Continued research is needed to elucidate the mechanisms behind long-term complications like liver adenomas, renal disease, and osteopenia.
  • Further investigation into endogenous glucose production and leukocyte defects may reveal new therapeutic targets.